New interventions are available for the prevention of respiratory syncytial virus (RSV) disease in young infants. We aimed to assess the potential impact and cost-effectiveness of using a long-acting monoclonal antibody (RSV mAb) or maternal RSV vaccine in the Argentine context. Methods. We used...
year-round maternal vaccination, and the effect of under-ascertainment for older adults. Results The model was able to match the various RSV datasets. Replacing the current short-acting mAB for high-risk infants with long-acting mAbs prevented 1.1% of RSV-specific hospitalisations in infants per...
Learn about Beyfortus, an RSV prevention treatment for infants. Get product details, clinical insights, and resources for healthcare professionals.
(20)康方生物 x Summit Therapeutics:Ivonescimab — IgG1κ-[scFv]2双特异性抗体 Ivonescimab(依达方®,依沃西单抗)是一种四价、双特异性抗体,可同时与VEGF-A、PD-1结合,竞争性阻断VEGF-A和PD-1与其配体的相互作用,发挥抗肿瘤活性,主要用于治疗非小细胞肺癌(NSCLC)。在一项3期临床试验HARMONi-2中,Ivone...
Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nat. Microbiol. 2, 16272 (2017). Article PubMed PubMed Central Google Scholar Goodwin, E. et al. Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that ...
Palivizumab is a potent anti-RSV mAb that is about 50-fold more potent than RSV-IGIV, and since obtaining regulatory approval in 1998 it has been used extensively to help prevent severe RSV disease in high-risk infants and children. However, a very small number of patients receiving the ...
Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis...
The Centers for Disease Control and Prevention (CDC) has recommended routine use of the mAb in all infants below 8 months of age born during or entering their first RSV season and in high-risk children aged 8-19 months of age entering their second RSV season. Chisholm continue...
ample room for improvement exists. Pfizer’s maternal vaccine does not substantially outperform the protection afforded by monoclonal antibody administration in infants; and GSK’s leading vaccine for the elderly does not adequately protect in the 80+ elderly or the frail where they achieve only 34 ...
帕利珠单抗(Synagis)是FDA批准的首个用于预防高风险婴儿因细支气管炎住院的人源化mAb。帕利珠单抗在首个RSV季节的五个月里,每月以15 mg/kg的剂量通过肌肉注射给药,以预防儿童严重的RSV LRTI。帕利珠单抗结合RSV融合(F)蛋白上的抗原位点A,这是一个高度保守的区域,能够通过结合病毒表面的RSV融合蛋白阻止膜融合过程...